Bicara, Zenas outline plans for $180M IPOs amid restored optimism for biotech debuts
Bicara Therapeutics and Zenas BioPharma are now a step closer to kicking open a mini-IPO window for drug developers this fall.
The startups outlined plans …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
